miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal

miRagen Restructures to Focus on Fibrosis, Inks $20M Stock Deal

Source: 
Xconomy
snippet: 

MicroRNA therapies developer miRagen Therapeutics is scaling back work on its most advanced cancer drug candidate and shifting resources to a compound being developed to treat fibrosis in the lungs.